Corbus Pharmaceuticals Holdings, Inc. CRBP
3.93 USD +0.41 (+11.65%)
At closeNov 10, 2026, 4:10 PM EST
3.93 0.00 0.00%
After hours · Nov 10, 4:10 PM ET
3.21 Day range 3.98
2.81 52-week range 12.88
- YTD
- -51.72%
- 1 year
- -62.43%
News
benzinga.com Corbus Pharmaceuticals Q3 EPS $(1.81) Misses $(1.20) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.20) by 50.83 percent. This is a 4.74 percent increase over…
globenewswire.com Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November NORWOOD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen,…- benzinga.com Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase…
benzinga.com HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.
benzinga.com Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects' Corbus Pharmaceuticals reports positive Phase 1b trial results for obesity drug CRB-913, demonstrating significant 12-week weight loss.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
benzinga.com Market-Moving News for September 14th GLW: -8% | Corning shares are trading lower after the company announced a $2 billion offering. ELMT: 49% | Elmet Group Lands $450M US Government Investment To Expand Tungsten Manufacturing, To Invest…
benzinga.com Corbus Pharma Announces Topline Data From CANYON-1 Phase 1b Trial Of CRB-913 Demonstrating Statistically Significant And Clinically Meaningful Weight Loss In Obesity CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric…
benzinga.com Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
benzinga.com Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host…- benzinga.com Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48 Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.
benzinga.com HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $40 to $35.- benzinga.com Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.26) by 43.65 percent. This is a 25.69 percent decrease over…
- benzinga.com Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the last patient has completed their last clinical…
- benzinga.com Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34 Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $44 to $34.
benzinga.com Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52 Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $54 to $52.- benzinga.com Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30 Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $38 to $30.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $40 price target.
- benzinga.com Corbus Pharma Reports Updated Data From Phase 1/2 Clinical Study Of CRB-701, Next-Gen Nectin-4 Targeted Antibody Drug Conjugate Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forwardConfirmed ORR of 42.9%…
- benzinga.com Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44 Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $40 to $44.
- benzinga.com Corbus Pharmaceuticals To Discuss Updated Data For Its Phase 1/2 Trial Of CRB-701 Antibody Drug Candidate To Treat Head And Neck Squamous Cell Carcinoma Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team…
- benzinga.com Jefferies Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $33 Jefferies analyst Maury Raycroft maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $36 to $33.
- benzinga.com Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $54 Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $57 to $54.
- benzinga.com Guggenheim Reiterates Buy on Corbus Pharmaceuticals, Maintains $45 Price Target Guggenheim analyst Paul Jeng reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $45 price target.
benzinga.com Corbus Pharmaceuticals Q1 EPS $(1.23) Misses $(1.22) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(1.22) by 0.82 percent. This is a 11.51 percent increase over…
benzinga.com Guggenheim Initiates Coverage On Corbus Pharmaceuticals with Buy Rating, Announces Price Target of $45 Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and announces Price Target of $45.- benzinga.com Corbus Pharmaceuticals Doses Last Participant In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced the last patient has been enrolled and…
benzinga.com Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck cancer opportunity and obesity pipeline.- benzinga.com Corbus Secures FDA Alignment On CRB-701 Registrational Studies For HNSCC And Cervical Cancer; Updated Phase 1/2 Data Set For ASCO 2026 FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701…
- benzinga.com Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $57 Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $53 to $57.
benzinga.com Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways 
benzinga.com Corbus Pharmaceuticals Q4 EPS $(1.25) Beats $(1.38) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.25) per share which beat the analyst consensus estimate of $(1.38) by 9.42 percent. This is a 60.26 percent decrease over losses…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Corbus Pharmaceuticals Highlights Safe, Well-Tolerated CRB-913 Phase 1a Results With Emerging Evidence Of Weight Loss In Obesity CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Roku, SPS Commerce, Newell Brands And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Cannabis Stock Gainers And Losers From July 16, 2025
- benzinga.com Cannabis Stock Movers For July 15, 2025
- benzinga.com Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 9, 2025
- benzinga.com Marijuana Stock Movers For July 2, 2025
- benzinga.com Cannabis Stock Movers For June 30, 2025
- benzinga.com Cannabis Stock Movers For June 27, 2025
- benzinga.com Cannabis Stock Gainers And Losers From June 26, 2025
- benzinga.com Cannabis Stock Gainers And Losers From June 25, 2025